16. April 2024 | Corporate News

Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets

  • Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record years (2022: EUR 11.3 million)
  • Important progress for Carragelose with new distribution partners and new products as well as Marinosolv assets with improved stability for lead products
  • Outlook 2024 and beyond: Primary goal to achieve operating profitability through commercialization of Carragelose and Marinosolv assets

 

The full press release is available as download here: 

Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
(93 KB)